Development of stable liquid formulations for oligonucleotides

[Display omitted] Oligonucleotide-based therapeutics have been implemented as a new therapeutic modality in biotech industry, which offers the opportunity to develop formulation platforms for robust parenteral formulations. The aim of this study was to gain a better understanding of stabilizing/de-s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmaceutics and biopharmaceutics 2018-08, Vol.129, p.80-87
Hauptverfasser: Poecheim, Johanna, Graeser, Kirsten A., Hoernschemeyer, Joerg, Becker, Gerhard, Storch, Kirsten, Printz, Miriam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 87
container_issue
container_start_page 80
container_title European journal of pharmaceutics and biopharmaceutics
container_volume 129
creator Poecheim, Johanna
Graeser, Kirsten A.
Hoernschemeyer, Joerg
Becker, Gerhard
Storch, Kirsten
Printz, Miriam
description [Display omitted] Oligonucleotide-based therapeutics have been implemented as a new therapeutic modality in biotech industry, which offers the opportunity to develop formulation platforms for robust parenteral formulations. The aim of this study was to gain a better understanding of stabilizing/de-stabilizing effects of different formulation parameters on unconjugated and N-acetylgalactosamine (GalNAc) conjugated single stranded oligonucleotides with locked nucleic acid modifications (LNA SSO), as model oligonucleotides. Various buffer systems, pH levels and different excipients were evaluated to optimize conditions for LNA SSO in liquid formulations. LNA SSO were exposed to different temperature conditions, mechanical stress as well as oxidative conditions, and the maximum feasible LNA SSO concentrations regarding handling and processing were determined. Finally, options for terminal sterilization of LNA SSO were evaluated. Results show that the tested LNA SSO were most stable under slightly alkaline conditions. A decrease in viscosity was best accomplished in the presence of spermine and lysine. Heat treatment and gamma irradiation caused high levels of degradation of the LNA SSO. Crucial formulation parameters, as identified in this study, should contribute to a significant increase in future productivity in drug product development for single-stranded oligonucleotides.
doi_str_mv 10.1016/j.ejpb.2018.05.029
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2045282135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641117314248</els_id><sourcerecordid>2045282135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-4c423cae86c7a5cd921f0e5f4b3408c092ff44bba76f53d265cdc8f6051a91c23</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozjj6B1xIl25a82xTEEHGJwy40XVI0xtJSZuZphX897bM6NLV5cB3DtwPoUuCM4JJftNk0GyrjGIiMywyTMsjtCSyYCnjnByjJS5ZmeackAU6i7HBGPNCyFO0oKWcaMmW6O4BvsCHbQvdkASbxEFXHhLvdqOrExv6dvR6cKGLc0iCd5-hG42HMLga4jk6sdpHuDjcFfp4enxfv6Sbt-fX9f0mNUzkQ8oNp8xokLkptDB1SYnFICyvGMfS4JJay3lV6SK3gtU0nxgjbY4F0SUxlK3Q9X5324fdCHFQrYsGvNcdhDEqirmgkhImJpTuUdOHGHuwatu7VvffimA1e1ONmr2p2ZvCQk0mptLVYX-sWqj_Kr-iJuB2D8D05ZeDXkXjoDNQux7MoOrg_tv_AVVmfz4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2045282135</pqid></control><display><type>article</type><title>Development of stable liquid formulations for oligonucleotides</title><source>Elsevier ScienceDirect Journals</source><creator>Poecheim, Johanna ; Graeser, Kirsten A. ; Hoernschemeyer, Joerg ; Becker, Gerhard ; Storch, Kirsten ; Printz, Miriam</creator><creatorcontrib>Poecheim, Johanna ; Graeser, Kirsten A. ; Hoernschemeyer, Joerg ; Becker, Gerhard ; Storch, Kirsten ; Printz, Miriam</creatorcontrib><description>[Display omitted] Oligonucleotide-based therapeutics have been implemented as a new therapeutic modality in biotech industry, which offers the opportunity to develop formulation platforms for robust parenteral formulations. The aim of this study was to gain a better understanding of stabilizing/de-stabilizing effects of different formulation parameters on unconjugated and N-acetylgalactosamine (GalNAc) conjugated single stranded oligonucleotides with locked nucleic acid modifications (LNA SSO), as model oligonucleotides. Various buffer systems, pH levels and different excipients were evaluated to optimize conditions for LNA SSO in liquid formulations. LNA SSO were exposed to different temperature conditions, mechanical stress as well as oxidative conditions, and the maximum feasible LNA SSO concentrations regarding handling and processing were determined. Finally, options for terminal sterilization of LNA SSO were evaluated. Results show that the tested LNA SSO were most stable under slightly alkaline conditions. A decrease in viscosity was best accomplished in the presence of spermine and lysine. Heat treatment and gamma irradiation caused high levels of degradation of the LNA SSO. Crucial formulation parameters, as identified in this study, should contribute to a significant increase in future productivity in drug product development for single-stranded oligonucleotides.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2018.05.029</identifier><identifier>PMID: 29802983</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Biopharmaceuticals characterization ; Forced conditions ; Formulation ; Oligonucleotides ; Stability</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2018-08, Vol.129, p.80-87</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-4c423cae86c7a5cd921f0e5f4b3408c092ff44bba76f53d265cdc8f6051a91c23</citedby><cites>FETCH-LOGICAL-c356t-4c423cae86c7a5cd921f0e5f4b3408c092ff44bba76f53d265cdc8f6051a91c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0939641117314248$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29802983$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poecheim, Johanna</creatorcontrib><creatorcontrib>Graeser, Kirsten A.</creatorcontrib><creatorcontrib>Hoernschemeyer, Joerg</creatorcontrib><creatorcontrib>Becker, Gerhard</creatorcontrib><creatorcontrib>Storch, Kirsten</creatorcontrib><creatorcontrib>Printz, Miriam</creatorcontrib><title>Development of stable liquid formulations for oligonucleotides</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted] Oligonucleotide-based therapeutics have been implemented as a new therapeutic modality in biotech industry, which offers the opportunity to develop formulation platforms for robust parenteral formulations. The aim of this study was to gain a better understanding of stabilizing/de-stabilizing effects of different formulation parameters on unconjugated and N-acetylgalactosamine (GalNAc) conjugated single stranded oligonucleotides with locked nucleic acid modifications (LNA SSO), as model oligonucleotides. Various buffer systems, pH levels and different excipients were evaluated to optimize conditions for LNA SSO in liquid formulations. LNA SSO were exposed to different temperature conditions, mechanical stress as well as oxidative conditions, and the maximum feasible LNA SSO concentrations regarding handling and processing were determined. Finally, options for terminal sterilization of LNA SSO were evaluated. Results show that the tested LNA SSO were most stable under slightly alkaline conditions. A decrease in viscosity was best accomplished in the presence of spermine and lysine. Heat treatment and gamma irradiation caused high levels of degradation of the LNA SSO. Crucial formulation parameters, as identified in this study, should contribute to a significant increase in future productivity in drug product development for single-stranded oligonucleotides.</description><subject>Biopharmaceuticals characterization</subject><subject>Forced conditions</subject><subject>Formulation</subject><subject>Oligonucleotides</subject><subject>Stability</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAUhYMozjj6B1xIl25a82xTEEHGJwy40XVI0xtJSZuZphX897bM6NLV5cB3DtwPoUuCM4JJftNk0GyrjGIiMywyTMsjtCSyYCnjnByjJS5ZmeackAU6i7HBGPNCyFO0oKWcaMmW6O4BvsCHbQvdkASbxEFXHhLvdqOrExv6dvR6cKGLc0iCd5-hG42HMLga4jk6sdpHuDjcFfp4enxfv6Sbt-fX9f0mNUzkQ8oNp8xokLkptDB1SYnFICyvGMfS4JJay3lV6SK3gtU0nxgjbY4F0SUxlK3Q9X5324fdCHFQrYsGvNcdhDEqirmgkhImJpTuUdOHGHuwatu7VvffimA1e1ONmr2p2ZvCQk0mptLVYX-sWqj_Kr-iJuB2D8D05ZeDXkXjoDNQux7MoOrg_tv_AVVmfz4</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Poecheim, Johanna</creator><creator>Graeser, Kirsten A.</creator><creator>Hoernschemeyer, Joerg</creator><creator>Becker, Gerhard</creator><creator>Storch, Kirsten</creator><creator>Printz, Miriam</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201808</creationdate><title>Development of stable liquid formulations for oligonucleotides</title><author>Poecheim, Johanna ; Graeser, Kirsten A. ; Hoernschemeyer, Joerg ; Becker, Gerhard ; Storch, Kirsten ; Printz, Miriam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-4c423cae86c7a5cd921f0e5f4b3408c092ff44bba76f53d265cdc8f6051a91c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biopharmaceuticals characterization</topic><topic>Forced conditions</topic><topic>Formulation</topic><topic>Oligonucleotides</topic><topic>Stability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poecheim, Johanna</creatorcontrib><creatorcontrib>Graeser, Kirsten A.</creatorcontrib><creatorcontrib>Hoernschemeyer, Joerg</creatorcontrib><creatorcontrib>Becker, Gerhard</creatorcontrib><creatorcontrib>Storch, Kirsten</creatorcontrib><creatorcontrib>Printz, Miriam</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poecheim, Johanna</au><au>Graeser, Kirsten A.</au><au>Hoernschemeyer, Joerg</au><au>Becker, Gerhard</au><au>Storch, Kirsten</au><au>Printz, Miriam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of stable liquid formulations for oligonucleotides</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2018-08</date><risdate>2018</risdate><volume>129</volume><spage>80</spage><epage>87</epage><pages>80-87</pages><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted] Oligonucleotide-based therapeutics have been implemented as a new therapeutic modality in biotech industry, which offers the opportunity to develop formulation platforms for robust parenteral formulations. The aim of this study was to gain a better understanding of stabilizing/de-stabilizing effects of different formulation parameters on unconjugated and N-acetylgalactosamine (GalNAc) conjugated single stranded oligonucleotides with locked nucleic acid modifications (LNA SSO), as model oligonucleotides. Various buffer systems, pH levels and different excipients were evaluated to optimize conditions for LNA SSO in liquid formulations. LNA SSO were exposed to different temperature conditions, mechanical stress as well as oxidative conditions, and the maximum feasible LNA SSO concentrations regarding handling and processing were determined. Finally, options for terminal sterilization of LNA SSO were evaluated. Results show that the tested LNA SSO were most stable under slightly alkaline conditions. A decrease in viscosity was best accomplished in the presence of spermine and lysine. Heat treatment and gamma irradiation caused high levels of degradation of the LNA SSO. Crucial formulation parameters, as identified in this study, should contribute to a significant increase in future productivity in drug product development for single-stranded oligonucleotides.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29802983</pmid><doi>10.1016/j.ejpb.2018.05.029</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0939-6411
ispartof European journal of pharmaceutics and biopharmaceutics, 2018-08, Vol.129, p.80-87
issn 0939-6411
1873-3441
language eng
recordid cdi_proquest_miscellaneous_2045282135
source Elsevier ScienceDirect Journals
subjects Biopharmaceuticals characterization
Forced conditions
Formulation
Oligonucleotides
Stability
title Development of stable liquid formulations for oligonucleotides
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A42%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20stable%20liquid%20formulations%20for%20oligonucleotides&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Poecheim,%20Johanna&rft.date=2018-08&rft.volume=129&rft.spage=80&rft.epage=87&rft.pages=80-87&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2018.05.029&rft_dat=%3Cproquest_cross%3E2045282135%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2045282135&rft_id=info:pmid/29802983&rft_els_id=S0939641117314248&rfr_iscdi=true